600276 恒瑞医药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)10.95214.73910.99110.72813.831
总资产报酬率 ROA (%)9.71013.4939.9889.57012.245
投入资产回报率 ROIC (%)10.49514.57210.64810.33213.551

边际利润分析
销售毛利率 (%)86.21986.24984.55283.61285.556
营业利润率 (%)28.56926.76721.51619.32718.007
息税前利润/营业总收入 (%)26.21623.57418.35616.44015.936
净利润/营业总收入 (%)24.84122.64518.74617.93217.309

收益指标分析
经营活动净收益/利润总额(%)97.82397.30798.68388.90592.080
价值变动净收益/利润总额(%)0.8891.575-2.30211.6895.590
营业外收支净额/利润总额(%)-3.314-4.476-5.202-3.615-4.445

偿债能力分析
流动比率 (X)6.5469.71912.2528.5008.875
速动比率 (X)6.1979.05411.3467.8278.168
资产负债率 (%)12.1408.0696.2849.3419.409
带息债务/全部投入资本 (%)5.878-0.0540.9724.0481.586
股东权益/带息债务 (%)1,589.374-184,059.23510,140.5082,350.5206,155.215
股东权益/负债合计 (%)717.3491,125.2271,470.724955.631947.456
利息保障倍数 (X)-18.251-11.518-8.756-7.428-12.216

营运能力分析
应收账款周转天数 (天)58.27965.02587.44489.03867.442
存货周转天数 (天)217.905221.301243.282250.552201.115